top of page

Custom Ba/F3 RTK Cell Line Development Services

The IL-3-dependent murine Ba/F3 system remains the gold standard for dissecting oncogene addiction, profiling IC50 shifts, and mapping secondary TKI resistance mechanisms. However, generating stable, IL-3-independent Ba/F3 variant lines in-house is time-consuming and often hindered by heterogeneous population kinetics, leaky growth backgrounds, or low transduction efficiency.

​

In addition to our ready-to-use, off-the-shelf EGFR, HER2, and FLT3 stable mutant cell lines, Signosis provides full end-to-end custom engineering of Ba/F3 cell lines harboring your specific receptor tyrosine kinase (RTK) variants, clinical resistance mutations, or novel oncogenic fusions. Every custom line undergoes rigorous single-cell clonal selection to guarantee reproducible growth kinetics, high transgene dependence, and reliable drug-response curves.

​

Applications

  • Kinase inhibitor screening

  • IC50 and potency determination

  • Drug selectivity profiling

  • Resistance mechanism studies

  • Lead optimization

  • Translational oncology research

​

Whether you need established variants or a newly discovered, proprietary mutation, we design and build bespoke cell lines to match your specific pipeline needs.  We can also perform downstream IC50 profiling and drug candidate testing upon request.

Why Choose Signosis?

When pioneering targeted oncology therapies, you need an experienced partner with a proven track record in molecular oncology and custom cell line engineering. Signosis combines deep mechanistic insight into oncogene addiction with robust technical capabilities to accelerate your drug discovery pipeline.

​​
Our trusted expertise includes:

  • Trusted Industry Partner: Proudly trusted by leading biopharmaceutical companies (including industry leaders like Roche) to deliver specialized, high-performing cell models.

  • Expert Construct & Engineering Flexibility: Proven capability by our highly experienced scientific team to handle challenging targets, complex fusion oncogenes, and structural modifications using either optimized lentiviral transduction or custom standalone expression vectors.

  • Stringent Single-Cell Cloning: Elimination of population heterogeneity through strict clonal isolation, guaranteeing uniform transgene expression and reproducible IC50 assay performance.

  • Proven Biological Relevance: Rigorously engineered models designed to replicate true clinical resistance profiles and oncogenic behavior.

​

Our Rigorous Validation Pipeline
To ensure every custom Ba/F3 and RTK cell line is ready for high-throughput screening upon delivery, every project undergoes comprehensive functional and molecular verification:

  • Validated IL-3 Independence: Verified IL-3 independence ensuring true oncogene addiction and robust, predictable growth kinetics without cytokine supplementation.

  • Target Protein Verification: Confirmed expression and pathway activation via Western blot analysis using mutation-specific antibodies.

  • Custom Functional Profiling: Optional pilot IC50 screening against reference inhibitors to validate assay responsiveness.

​

Kinase Target Capabilities & Custom Development

Signosis is equipped to engineer Ba/F3 models across a broad spectrum of receptor tyrosine kinases, non-receptor kinases, and oncogenic fusions. All cell lines are generated via lentiviral transduction, and we can also provide standalone expression vectors if you prefer to handle generation in-house.

​​

Because clinical resistance profiles and novel mutations continuously evolve, our platform is entirely customizable. Whether you need established variants or a newly discovered, proprietary mutation, we design and build bespoke cell lines to match your specific pipeline needs. For all requests, including targets not listed below, please contact us at info@signosisinc.com.

VEGFR (KDR/FLK-1)

  • Wild-Type and Kinase Domain Variants:

    • VEGFR2 (KDR) WT

    • V916M

    • T925I

ALK

  • Fusions: EML4-ALK (Variants 1, 2, and 3)

  • Resistance Variants:

    • G1202R

    • L1196M

    • I1171T

    • F1174L

ROS1

  • Fusions: CD74-ROS1, EZR-ROS1, SDC4-ROS1

  • Resistance Variants:

    • G2032R

    • D2033N

    • S1986Y

MET

  • Exon 14 Skipping: MET ex14del

  • Kinase Domain Resistance

    • Y1230H/C/S

    • D1228N/H

    • G1163R

RET

  • Fusions: KIF5B-RET, CCDC6-RET

  • Resistance Variants:

    • V804M

    • V804L

    • G810R

    • G810S

CUSTOM AND PROPRIETARY KINASE TARGETS

Have a novel clinical variant, proprietary kinase sequence, drug-resistance mutation, or fusion construct?

​

Building on our experience generating Ba/F3 models for kinase-driven signaling studies, Signosis offers custom vector design, stable cell line engineering, single-cell cloning, and functional validation for virtually any RTK, non-receptor kinase, or oncogenic fusion provided by your team.

​

  • Potential project types include:

  • Novel clinical mutations

  • Drug-resistance variants

  • Kinase domain mutations

  • Fusion oncogenes

  • Proprietary therapeutic targets

  • Multi-mutation constructs

  • Wild-type control cell lines

​

Our team will work with you to design, engineer, validate, and deliver a custom Ba/F3 cell line tailored to your research objectives.

Explore Related Cell Line Panels

 

Not sure if you need a fully custom build? Browse our existing inventory of pre-validated, high-demand oncogenic models:

bottom of page